A data-only preview of Medico Remedies Q2 FY27 results, covering the Jun26 quarter, the Sep25 base quarter, five-quarter trend and valuation ahead of the September quarter announcement.

A factual preview of Medicamen Biotech Ltd. ahead of Q2 FY27 results, based on its own five-quarter revenue, margin and profit trend, including the Mar26 one-off noted in its data.

A data-driven preview of Marksans Pharma Q2 results for the September 2026 quarter, tracking five straight quarters of margin expansion, the Jun26 base and valuation.

A neutral, data-based preview of Krebs Biochemicals and Industries’s Q2 FY27 (September 2026 quarter) results, covering the expected date window, recent quarterly trends and valuation metrics, with no invented estimates.

A qualitative preview of the IPCA Laboratories Q2 results for the September 2026 quarter, covering the likely results date, the Jun26 and Sep25 comparison base, the five quarter trend and current valuation.

A factual preview of IOL Chemicals and Pharmaceuticals Q2 results for the September 2026 quarter: results date, Q1 FY27 numbers and valuation.

A results preview of Haleos Labs (formerly SMS Lifesciences) ahead of Q2 FY27, covering the expected date, Q1 FY27 recovery, base quarter and valuation.

Gujarat Themis Biosyn has held a 39-49 percent operating margin across five quarters. Here is the trend heading into Q2 FY27 results, based only on historical data.

Gufic Biosciences heads into its Q2 FY27 results with steady revenue growth and improving margins over the last five quarters. Here is the trend, without any fabricated forecasts.

A look at Granules India Ltd.’s expected Granules India Q2 results, covering the historical results pattern, recent quarterly trend, and current valuation ahead of the September 2026 quarter numbers.